Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Martin Moorhead on Role of Minimal Residual Disease in Leukemia and Lymphoma

Martin Moorhead, PhD
Published: Thursday, Jul 28, 2016


Martin Moorhead, PhD, Senior Vice President, Research & Development at Adaptive Biotechnologies Corp, discusses the role of minimal residual disease (MRD) in leukemia and lymphoma.
 
MRD is a hot topic right now in hematological malignancies, says Moorhead. Key opinion leaders are using it in their clinical research and there is a strong use of it in clinical trials.
 
MRD is being used as a surrogate endpoint to allow earlier readout of trials, says Moorhead. This is because as agents become more and more effective, progression-free survival (PFS) and overall survival (OS) endpoints take a longer time. A surrogate endpoint is very important for pharmaceutical companies to get results in a timelier fashion, says Moorhead.
SELECTED
LANGUAGE

Martin Moorhead, PhD, Senior Vice President, Research & Development at Adaptive Biotechnologies Corp, discusses the role of minimal residual disease (MRD) in leukemia and lymphoma.
 
MRD is a hot topic right now in hematological malignancies, says Moorhead. Key opinion leaders are using it in their clinical research and there is a strong use of it in clinical trials.
 
MRD is being used as a surrogate endpoint to allow earlier readout of trials, says Moorhead. This is because as agents become more and more effective, progression-free survival (PFS) and overall survival (OS) endpoints take a longer time. A surrogate endpoint is very important for pharmaceutical companies to get results in a timelier fashion, says Moorhead.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x